COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
14 hedge funds and large institutions have $1.02M invested in COSCIENS Biopharma Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
148% more capital invested
Capital invested by funds: $412K → $1.02M (+$611K)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
17% more funds holding
Funds holding: 12 → 14 (+2)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$670K |
| 2 |
Goldman Sachs
New York
|
+$22.3K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$22.3K |
| 4 |
AAM
Azzad Asset Management
Falls Church,
Virginia
|
+$11.2K |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$57K |
| 2 |
Morgan Stanley
New York
|
-$22.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$22.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$11.2K |
CSCI Hedge Fund Activity: Q2 2014 in Review
14 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2014, worth a combined $1.02M — up 148% from $412K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CSCI positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $670K. The largest seller was BlackRock Institutional Trust, exiting entirely with an estimated $57K sold.
- 14 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2014, up from 12 in Q1 2014.
- Funds reported $1.02M of COSCIENS Biopharma Inc. Common Stock stock for Q2 2014, up 148% quarter-over-quarter.
- 5 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2014 and 3 closed out, a net change of +2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2014 was Renaissance Technologies, an estimated $670K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2014 was BlackRock Institutional Trust, an estimated $57K sold.
Based on aggregated 13F filings for Q2 2014.